Session » RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World (0813–0845)

Date: Sunday, November 7, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 0845

A Non-Interventional Prospective Observational Study of Treatment with Etanercept Biosimilar (SB4) in Rheumatoid Arthritis in Real Life Clinical Practice; Interim Analysis of the ‘BENEFICIAL’ Study

8:30AM-10:30AM: Abstract Number: 0819

A Real-World 2-Year Prospective Study of Medication Tapering in Patients with RA in Sustained Remission in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort

8:30AM-10:30AM: Abstract Number: 0825

An Investigator-initiated Multicenter Randomized Study in Early Rheumatoid Arthritis of Active Conventional Therapy versus Three Biological Treatments: 48 Week Clinical and Radiographic Results of the NORD-STAR Trial

8:30AM-10:30AM: Abstract Number: 0816

Analysis of Abatacept Treatment Retention and Efficacy According to Disease Duration and Treatment Line in a Real-World Setting

8:30AM-10:30AM: Abstract Number: 0821

Baseline Characteristics Predictive of Remission in Patients with RA Following Treatment with IV Abatacept: Post Hoc Analysis of a Real-world Observational Study

8:30AM-10:30AM: Abstract Number: 0818

Biologics Initiation in Moderate vs Severe Rheumatoid Arthritis Patients: Prospective Observational Study from a Canadian Registry

8:30AM-10:30AM: Abstract Number: 0817

Biosimilar Infliximab Therapy in Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis: A Long-term Follow-up Study on Infliximab-naive Patients and Switched Patients from the Originator to the Biosimilar CT-P13

8:30AM-10:30AM: Abstract Number: 0834

Comparative Effectiveness of TNF Inhibitor vs IL-6 Receptor Inhibitor as Monotherapy or Combination Therapy with Methotrexate in Patients with Rheumatoid Arthritis: Analysis from CorEvitas’ RA Registry

8:30AM-10:30AM: Abstract Number: 0839

Comparative Treatment Effectiveness in Rheumatoid Arthritis with and Without Concomitant Sjögren’s Syndrome – Results from the Swiss Clinical Quality Management Cohort

8:30AM-10:30AM: Abstract Number: 0832

Consistency in Time to Response with Upadacitinib as Monotherapy or Combination Therapy and Across Patient Populations with Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 0826

Diagnosis, Treatment and Utilization Changes in Rheumatoid Arthritis Patients Before and During COVID-19

8:30AM-10:30AM: Abstract Number: 0827

Discontinuation Rate of Tofacitinib as Monotherapy Is Similar Compared to Combination Therapy with Methotrexate in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada

8:30AM-10:30AM: Abstract Number: 0833

Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in German Real-World Practice: Interim Results from a Post-Marketing Observational Study

8:30AM-10:30AM: Abstract Number: 0836

Flare After Switching from Intravenous Tocilizumab to Subcutaneous Formulation in Patients with Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 0835

Immunogenicity of Rituximab Biosimilar GP2013 in Chronic Inflammatory Rheumatic Disorders in Daily Clinical Practice

8:30AM-10:30AM: Abstract Number: 0815

Implementing Treat to Target (TTT) for Rheumatoid Arthritis (RA) Through a Virtual Learning Collaborative (LC) Program During COVID

8:30AM-10:30AM: Abstract Number: 0813

Improvement in Clinical Disease Activity and Patient-Reported Outcomes After 6 Months of Treatment with Abatacept, Stratified by Line of Therapy, in Patients with RA: Results from a Large, US, National Observational Study

8:30AM-10:30AM: Abstract Number: 0822

Local Tolerance of GP2017, an Adalimumab Biosimilar with Low Citrate Concentration Formulation, in Healthy Volunteers and Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis

8:30AM-10:30AM: Abstract Number: 0828

Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 3 Years from the SELECT-COMPARE Study

8:30AM-10:30AM: Abstract Number: 0840

Modelling of Disease Activity in Patients with Inflammatory Arthropathies Treated with Etanercept Originator or Biosimilar as First-Line Biologic: A Real-World Observational Study Using the OPAL Dataset

8:30AM-10:30AM: Abstract Number: 0814

Patient Characteristics, Efficacy, and Treatment Patterns of Tofacitinib Monotherapy in Patients with RA: Contextualization of Randomized Controlled Trial Results with Real-world Data

8:30AM-10:30AM: Abstract Number: 0841

Persistence on JAK Inhibitors in Daily Practice: Evaluation of the Rhadar-registry

8:30AM-10:30AM: Abstract Number: 0823

Pharmacokinetic and Pharmacodynamic Evaluation of a Proposed Biosimilar MSB11456 versus Both the US-licensed and EU-approved Tocilizumab: Results of a Randomized, Double-blind, Parallel-group, Single-dose Trial in Healthy Adults

8:30AM-10:30AM: Abstract Number: 0824

Physicians’ Reasons for Prescribing Janus Kinase Inhibitors (JAKi) in Patients with Rheumatoid Arthritis, and Associated Alignment Between Physicians and Patients in a Real-world Clinical Setting

8:30AM-10:30AM: Abstract Number: 0838

Predictors of Treatment for Inflammatory Arthritis with Immune Modulating Medications (IMM) in US Veterans

8:30AM-10:30AM: Abstract Number: 0843

Prevalence and Trends of Infections in Hospitalized Patients with Rheumatoid Arthritis in the United States

8:30AM-10:30AM: Abstract Number: 0831

Safety and Efficacy of Tofacitinib vs TNF Inhibitors in RA Patients Aged 50 Years or Older with One or More Cardiovascular Risks: Results from a Phase 3b/4 Randomized Safety Trial

8:30AM-10:30AM: Abstract Number: 0830

Smartphone Assisted Patient Initiated Care Safely Reduces Outpatient Clinic Visits in Patients with Rheumatoid Arthritis: Results from a Randomized Controlled Trial

8:30AM-10:30AM: Abstract Number: 0837

Sustainability of Response Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Results Through 3 Years from the SELECT-COMPARE Trial

8:30AM-10:30AM: Abstract Number: 0844

Switching Biologics and Failure to Attain Remission in the First Year Predicts bDMARD Refractory Disease in Rheumatoid Arthritis: A 15-year Follow up of the Alberta Biologics Pharmacovigilance Cohort

8:30AM-10:30AM: Abstract Number: 0829

Tapering and Withdrawal of Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Inflammatory Arthritis: A Systematic Review and Meta-Analyses of Randomised Trials

8:30AM-10:30AM: Abstract Number: 0820

The PROPER Study: Results of the First 48-week Interim Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis

8:30AM-10:30AM: Abstract Number: 0842

What Is the Success Rate in Clinical Trials of Discontinuation Glucocorticoids After Their Use as Bridging Therapy – a Systematic Literature Review

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].